Perspective on adaptive designs: 4 years European Medicines Agency reflection paper, 1 year draft US FDA guidance – where are we now?
Brenda L. Gaydos, Armin Koch, Frank Miller, Martin Posch, Marc Vandemeulebroecke, Sue‐Jane Wang · Clinical Investigation · 2012
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Clinical Investigation · OMICS Publishing Group · article · 2012
Abstract
Adaptive clinical trials attract great attention from academia, industry and regulatory authorities. Both the European Medicines Agency and the US FDA have clarified their positions in recently issued (final or draft) guidance documents. With this background, current trends and issues were analyzed in a panel discussion at the International Society for Biopharmaceutical Statistics (ISBS) meeting in March 2011. In this article, members of the panel summarize their thoughts based on this discussion.
Open the resolved locator · 10.4155/cli.12.5
Metadata licence: OpenAlex metadata (CC0)